Page 67 - Approval Program News Today

/PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming March 8, 2021 deadline to file a lead plaintiff motion in the class...

NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...

NEW YORK, Jan. 07, 2021 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Tricida, Inc. (“Tricida” or the

Search jobs 07-Jan-2021 Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Tricida, Inc. (TCDA) on Behalf of Investors LOS ANGELES--(BUSINESS WIRE)--$TCDA#CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Tricida, Inc. (“Tricida” or the “Company”) (NASDAQ: TCDA) investors concerning ...

/PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Tricida, Inc....

Search jobs 08-Jan-2021 TRICIDA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Tricida, Inc. and Encourages Investors to Contact the Firm NEW YORK--(BUSINESS WIRE)--#ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of in...

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Tricida, Inc. ("Tricida" or the "Company") (NASDAQ: TCDA) and...

Author Bio Rich has been a Fool since 1998 and writing for the site since 2004. After 20 years of patrolling the mean streets of suburbia, he hung up his badge and gun to take up a pen full time. Having made the streets safe for Truth, Justice, and Krispy Kreme donuts, he now patrols the markets looking for companies he can lock up as long-term holdings in a portfolio. His coverage reflects his passion for motorcycles, booze, and guns (though typically not all exercised ...

December 21, 2020 --Oral XPOVIO® Approval as Combination Therapy in Patients with Multiple Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO® Addressable Patient Population - -- Oral XPOVIO® is Now the Only Approved Multiple Myeloma Drug Indicated as Part of a Once-Weekly Bortezomib Combination Regimen - -- First Multiple Myeloma Drug with a New Mechanism of Action Approved by the FDA in the Second-Line Setting Since 2016 - -- FDA Approval Comes Approximately Three Mo...

(2) DJ EQS-News: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy EQS-News / 21/12/2020 / 15:21 UTC+8 Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy --Oral ...